ResMed Inc. stock advances amid strong Q2 earnings and digital health push, drawing DACH investor interest

ResMed Inc. (ISIN: US7611521078) reports robust Q2 FY26 results with 11% revenue growth to $1.42 billion, highlighting margin expansion in sleep apnea devices and digital solutions. German-speaking investors eye the NYSE-listed medtech leader for its defensive healthcare exposure and European market penetration. Latest developments signal sustained profitability amid aging population trends.

ResMed Inc., a leader in sleep apnea treatment and digital health solutions, delivered impressive Q2 FY26 results, driving its stock higher on the NYSE. Revenue climbed 11% to $1.42 billion, fueled by demand for connected CPAP devices and software platforms. For DACH investors, this underscores ResMed's resilience in a volatile market, with strong European sales and a focus on chronic disease management aligning with regional healthcare priorities.

As of: 21.03.2026

By Dr. Elena Hartmann, Senior MedTech Analyst – Tracking ResMed's digital transformation as it reshapes sleep health markets for global investors.

Recent Earnings Momentum Fuels Optimism

ResMed's Q2 performance marked a continuation of profitable growth. The company achieved significant margin expansion alongside EPS growth, reflecting operational efficiency in its core mask and device segments. Investors reacted positively, with the ResMed Inc. stock trading at $227.41 USD on the NYSE in recent sessions, following a minor dip but maintaining upward trajectory.

Sleep apnea device sales remain the backbone, but digital health contributions are accelerating. ResMed's myAir app and cloud-connected therapy data are boosting patient adherence and recurring revenue. This blend of hardware and software positions the firm uniquely in medtech.

For the trailing 12 months, ResMed generated substantial free cash flow, supporting dividends and buybacks. The payout ratio sits comfortably at 22.19%, with a yield around 1.16% on ASX shares, though NYSE liquidity dominates for institutional trading.

Financial Health Underlines Stability

ResMed boasts a fortress balance sheet. Net cash stands at $545.50 million AUD equivalent, with debt-to-equity at a low 0.14. Current ratio of 3.44 signals ample liquidity for R&D and acquisitions.

Return on equity reaches 25.86%, outpacing many healthcare peers. This efficiency stems from high gross margins near 60% and operating margins above 32%. In an industry prone to reimbursement pressures, ResMed's pricing power shines through.

Capital expenditures remain disciplined at -137.07 million, yielding robust free cash flow of 2.53 billion. Such metrics appeal to DACH investors seeking quality compounders with low cyclicality.

Employee productivity is notable, with revenue per head at 740,537 AUD. ResMed's 10,600 workforce drives innovation without bloat, a key differentiator in labor-intensive medtech.

Digital Health Expansion as Key Catalyst

ResMed's pivot to digital therapeutics is transformative. Platforms like AirSense 11 integrate telehealth, monitoring patient compliance remotely. This shift reduces clinic visits, appealing to cost-conscious European systems.

In Q2 FY26, digital revenue grew faster than hardware, with SaaS-like margins emerging. ResMed processes vast datasets from millions of users, creating moats via network effects and AI-driven insights.

Competitors lag in connected ecosystems. Philips' recall issues handed market share to ResMed, solidifying its dominance. For DACH portfolios, this tech overlay on defensive healthcare offers growth without excessive risk.

Investor Relevance for DACH Markets

German-speaking investors find ResMed compelling due to its European footprint. Germany, with high sleep disorder prevalence, drives regional sales. ResMed's devices comply with stringent MDR regulations, easing adoption.

DACH healthcare spending rises with demographics. ResMed benefits from public-private partnerships in Austria and Switzerland, where telehealth gains traction post-pandemic. Dividend reliability suits conservative portfolios.

NYSE listing ensures liquidity, accessible via local brokers. Compared to pure EU medtech, ResMed's US scale provides diversification. Institutional moves, like TKG Advisors adding shares, signal confidence.

Sector Dynamics and Competitive Edge

Sleep apnea market expands at double-digits, driven by obesity trends. ResMed holds over 50% US share, extending globally. Product roadmaps feature slimmer masks and quieter devices, enhancing compliance.

ROIC of 16.80% reflects capital discipline. Unlike device-heavy peers, ResMed's software margins scale higher. This hybrid model weathers reimbursement cuts better.

Valuation metrics like EV/EBITDA at 21.00 suggest premium but justified pricing for growth. Analyst consensus eyes sustained EPS expansion into FY27.

Risks and Open Questions Ahead

Reimbursement headwinds loom in mature markets. US Medicare changes could pressure volumes, though ResMed's premium positioning mitigates. Supply chain vulnerabilities persist post-global disruptions.

Competition intensifies from Chinese entrants, but IP barriers protect core tech. Overbought RSI signals near-term pullback risk, with support at $255.16 USD on NYSE.

Regulatory scrutiny on digital health data privacy grows in EU. ResMed's compliance track record reassures, but execution remains key. Macro slowdowns may delay elective therapies.

Outlook and Strategic Positioning

Upcoming earnings on July 31, 2025, eyed for FY26 guidance. Consensus EPS at $2.46 suggests continued beats. ResMed's M&A war chest targets adjacent respiratory tech.

For DACH investors, ResMed blends growth, yield, and quality. Aging populations amplify demand, with digital moats ensuring longevity. Balanced portfolios benefit from this medtech stalwart.

Strategic focus on out-of-hospital care aligns with global shifts. ResMed's trajectory promises compounded returns, rewarding patient holders amid sector tailwinds.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.